Longevity & Cellular Kinetics: NMN (Nicotinamide Mononucleotide) Human Trials
Clinical trials in middle-aged and older adults demonstrate that oral NMN significantly elevates whole-blood NAD+ concentrations (up to 2.1x), enhances 6-minute walking test distance, and improves insulin sensitivity in postmenopausal women.
Key Clinical Takeaways & Systematic Review Summary
Clinical trials in middle-aged and older adults demonstrate that oral NMN significantly elevates whole-blood NAD+ concentrations (up to 2.1x), enhances 6-minute walking test distance, and improves insulin sensitivity in postmenopausal women.
- Evidence Classification: Rigorously graded under standardized Cochrane & GRADE systematic review protocols.
- Literature Benchmark Dosage: 500 mg – 900 mg daily.
- Pharmacokinetic Timing: Morning administration on an empty stomach to align with circadian NAMPT expression peaks..
- Active Primary PubMed Reference: PMID 35441979 (Science).
Participate in Paid Clinical Research Studies ($750–$2,200 Stipends)
Accredited medical research centers are actively enrolling qualified participants for metabolic health, incretin therapy, and longevity studies. All physician evaluations, lab panels, and investigational compounds are provided at zero cost.
Check Clinical Trial Match Eligibility →Interactive Clinical Calculators & Drug Interaction Checkers
Calculate individualized body-weight dosages, check contraindications against prescription medications, and analyze 24-hour synergy schedules using our free interactive tool suite: